Pretargeting for imaging and therapy in oncological nuclear medicine.

Clément BaillyCaroline Bodet-MilinCaroline RousseauAlain Faivre-ChauvetFrançoise Kraeber-BodéréJacques Barbet

Published in: EJNMMI radiopharmacy and chemistry (2017)

While pretargeting has shown promise and demonstrated preclinical and clinical proof of principle, full-scale clinical development programs are needed to translate pretargeting into a clinical reality that could ideally fit into current theranostic and precision medicine perspectives.

Keyphrases

high resolution
prostate cancer
bone marrow
radical prostatectomy
artificial intelligence
minimally invasive
virtual reality